检索

期
标题
作者
卷 24, 编号 2 (2022)
Combination therapy regimens in the treatment of metastatic renal cell carcinoma: A review
Zukov R., Chernyaev D., Zulkaidarova A.
PDF
(Rus)
卷 22, 编号 1 (2020)
ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution
Poddubnaya I., Al-Radi L., Byalik T., Kaplanov K., Molostvova V., Nikitin E., Pospelova T., Ptushkin V., Samoilova O., Stadnik E., Tumyan G.
PDF
(Rus)
卷 21, 编号 4 (2019)
The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution
Poddubnaya I., Bialik T., Glonina N., Kalashnikova O., Kaplanov K., Lapin V., Medvedeva N., Mikhailova N., Moiseeva T., Nikitin E., Pospelova T., Stadnik E.
PDF
(Rus)
卷 23, 编号 1 (2021)
Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
Bogdanov A., Moiseenko F., Egorenkov V., Bogdanov A., Volkov N., Fedyanin M.
PDF
(Rus)
卷 21, 编号 3 (2019)
Osimertinib for the first-line treatment of EGFR-positive non-small cell lung cancer
Reutova E., Laktionov K., Iudin D., Neliubina L., Gorokhova G., Egorova A.
卷 24, 编号 1 (2022)
Osimertinib and routine practice: the experience of the drug application in different clinical situations in case of metastatic non-small cell lung cancer with an EGFR mutation. Case report
Orlov S., Baldin P., Diuzeva N., Krechetova A., Mordovskiy A., Moskovchenko A., Musaeva N., Romanchuk O.
PDF
(Rus)
卷 23, 编号 3 (2021)
ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia
Bialik T., Vorob'ev V., Ionin V., Ysebaert L., Kaplanov K., Mendeleeva L., Nikitin E., Ptushkin V., Samoilova O., Stadnik E.
PDF
(Rus)
卷 15, 编号 3 (2013)
Gefitinib – terapiya vybora 1-y linii nemelkokletochnogo raka legkogo u bol'nykh s nalichiem mutatsiy v gene EGFR
Bolotina L.
卷 23, 编号 3 (2021)
Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
Goryaynov S.
PDF
(Rus)
卷 23, 编号 2 (2021)
Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence
Petrenko A., Kislova M., Dmitrieva E., Nikitin E.
PDF
(Rus)
卷 19, 编号 1 (2017)
The comparative pharmacoeconomic analysis of tyrosine kinase inhibitor Iressa® (gefitinib) with TKI Giotrif® (afatinib) as first-line therapy for patients with advanced non-small cell lung cancer associated with mutations in the epidermal growth factor receptor
Ryazhenov V.
PDF
(Rus)
卷 22, 编号 2 (2020)
Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
Odintsova S., Sviridenko M., Cheremnykh A., Filippova E., Urtenova M., Orlov S.
PDF
(Rus)
1 - 12 的 12 信息

检索提示:

  • 检索的名词区分大小写
  • 常用字词将被忽略
  • 默认情况下只有在查询结果满足所有检索词才返回（例如，隐含AND）
  • 使用OR结合多个检索词，便于查找含有这些检索词的文章，例如education OR research
  • 使用括号来创建更复杂的查询; 例如：archive ((journal OR conference) NOT theses)
  • 使用引号检索一个完整的词组; 例如： "open access publishing"
  • 使用-或者NOT排除一个检索词; 例如：online -politics or online NOT politics
  • 在检索词里使用 *作为通配符匹配任何字符序列; 例如., soci* morality 将符合含有 "sociological" or "societal"的词语

##common.cookie##